Patents by Inventor Dominique Latinne

Dominique Latinne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition comprising the LO-CD2a antibody
    Patent number: 7592006
    Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: September 22, 2009
    Assignee: Université Catholique de Louvain
    Inventors: Herve Bazin, Dominique Latinne
  • Method of treatment with anti-CD2 antibody LO-CD2b
    Patent number: 7250167
    Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: July 31, 2007
    Assignee: Université Catholique De Louvain
    Inventors: Hervé Bazin, Dominique Latinne, Pierre Gianello
  • LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
    Patent number: 6849258
    Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: February 1, 2005
    Assignees: Universite Catholique de Louvain, BioTransplant, Inc.
    Inventors: Hervé Bazin, Dominique Latinne, Ruth Kaplan, Thomas Kieber-Emmons, Christina E. Postema, Mary E. White-Scharf
  • Apoptosis of naive human NK cells by crosslinking of their Fc&ggr;RIIIa molecules with a rat IgG2b (LO-CD2a/BTI-322) or its IgG1 humanized monoclonal antibody
    Patent number: 6692743
    Abstract: Although the mechanism of induction of apoptosis through antibody dependent cellular cytotoxicity (ADCC) mediated by NK cells is well understood, little is known about the fate of the reactive NK cells. Nevertheless, it has been shown that NK cells previously activated by IL-2, but not naive NK cells, died by apoptosis after Fc&ggr;RIIIa crosslinking, or after engagement in cytolytic functions. It is demonstrated that apoptosis of naive NK cells is also observed after stimulation with a rat IgG2b anti CD2 mAb (LO-CD2a/BTI-322) or anti HLAI (LO-HLA-1)mAb. The NK apoptosis is rapid (within minutes), Fas-ligand and mRNA synthesis independent and does not require a cell contact. The intracellular mechanism of NK cell apoptosis is calcium, PKC and PLA2 dependent but calcineurin and P13 kinase independent. We suggest that NK cell apoptosis results from the crosslinking on the same cell surface of CD2 or HLA-I molecules and Fc&ggr;RIIIa that exhibits a high affinity for the rat IgG2b isotype.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: February 17, 2004
    Assignee: Universite Catholique de Louvain
    Inventors: Herve Bazin, Dominique Latinne
  • LO-CD2b antibody and uses thereof for inhibiting T cell activation and proliferation
    Publication number: 20030139579
    Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.
    Type: Application
    Filed: November 6, 2002
    Publication date: July 24, 2003
    Applicant: Universite Catholique de Louvain.
    Inventors: Herve Bazin, Dominique Latinne, Pierre Gianello
  • LO-CD2b antibody
    Patent number: 6541611
    Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: April 1, 2003
    Assignee: Universite Catholique de Louvain
    Inventors: Hervé Bazin, Dominique Latinne, Pierre Gianello
  • Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
    Patent number: 5951983
    Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 14, 1999
    Assignees: Universite Catholique de Louvain, Bio Transplant, Inc.
    Inventors: Herve Bazin, Dominique Latinne, Ruth Kaplan, Thomas Kieber-Emmons, Christina E. Postema, Mary E. White-Scharf